Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology, has received approval from the National Medical Products Administration for the clinical trial of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 injection is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Chengdu Kanghong Biotechnology Co., has received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar to Dupilumab [1] Group 1: Product Development - KH816 is developed as a biosimilar to Dupilumab, which is a fully human monoclonal antibody (IgG4 type) [1] - The mechanism of action involves specific binding to the IL-4Rα subunit shared by IL-4 and IL-13 receptor complexes, inhibiting the signaling pathways of IL-4 and IL-13 [1] Group 2: Therapeutic Applications - IL-4 and IL-13 mediated inflammation is a significant component in the pathogenesis of asthma, atopic dermatitis, nodular prurigo, and chronic obstructive pulmonary disease [1] - The inflammatory response involves various cell types expressing IL-4Rα, including mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, and goblet cells, as well as inflammatory mediators such as histamine, leukotrienes, cytokines, and chemokines [1] Group 3: Mechanism of Action - By blocking IL-4Rα, Dupilumab can inhibit the inflammatory responses induced by IL-4 and IL-13 cytokines, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE [1]

Core Viewpoint - The company Boan Biotechnology (06955) has announced that its self-developed drug BA6101 has received approval for market launch in Bolivia, which is a biosimilar to the reference drug Prolia® used for osteoporosis treatment [1][6]. Group 1: Stock Performance - Boan Biotechnology's stock price increased by 6.07%, currently trading at 9.96 HKD, with a trading volume of 54.81 million HKD [1][6]. Group 2: Product Approval - The Bolivian National Medicines and Health Technologies Agency (AGEMED) has approved the injection of BA6101 (60mg) for market launch [1][6]. - BA6101 is a biosimilar to Prolia®, which is widely used globally for the treatment of osteoporosis, and it shares the same indications as the reference drug [1][6]. Group 3: Global Development Strategy - BA6101 is developed based on the company's global research and development strategy, with plans for commercialization in multiple countries and regions [1][6]. - The company is currently in the approval process for BA6101's marketing authorization in the UK and plans to submit applications in Europe, the United States, Japan, and other regions [1][6].

Core Viewpoint - The company has announced an increase in trading volume of its H-shares on January 9, 2026, and confirmed no knowledge of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares by its controlling shareholder, Luye Pharma Group [1][2] Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which can be exchanged for 100.5 million H-shares held by Luye Pharma Group [1][2] - To comply with the agreement related to the exchangeable preferred shares, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer on the market [1] Group 2: Product Development and Approval - The company announced that its self-developed drug, BA6101 (60mg), has been approved for marketing by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2] - BA6101 is a biosimilar to the reference drug Prolia, widely used for the treatment of osteoporosis, and shares the same indications as the reference drug [2][3] - The development of BA6101 adhered to international guidelines, confirming its overall similarity to the reference drug in terms of quality, safety, and efficacy [3] Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and has established strategic partnerships for its commercialization in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [3] - The company aims to accelerate its international strategy by providing high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [3]

Core Insights - The Chinese biopharmaceutical industry has significantly advanced over the past decade, surpassing India in innovation and drug development, particularly in areas like Antibody-Drug Conjugates (ADC) [1][2] - The transformation of China's pharmaceutical sector began around 2015, marked by regulatory reforms that stimulated innovation and accelerated drug approval processes [3][4] Company Development - The company, founded by Dr. Luo Shun, has grown alongside the Chinese pharmaceutical industry, filling gaps in the market such as the production of serum-free cell culture media [2][4] - The establishment of the Ginspire platform focuses on the early research of biopharmaceuticals, leveraging AI and advanced technologies to enhance drug development efficiency [5] Market Position and Growth - The company has developed a robust CDMO (Contract Development and Manufacturing Organization) business, particularly in the ADC sector, which is expected to be a key growth area in the next 5 to 10 years [6][8] - The CDMO business has shown resilience, with a projected revenue growth of nearly 30% in 2024, despite industry challenges [8][10] International Expansion - The company is pursuing a dual-path international strategy, establishing a presence in markets such as Europe, Australia, and Southeast Asia, while also expanding production capacity abroad [12] - The company aims to meet international regulatory standards, including those from the EMA and FDA, to facilitate the approval of biopharmaceuticals [12][13] Competitive Landscape - The company emphasizes the importance of innovation and efficiency in maintaining competitiveness amid intense price competition in the Chinese pharmaceutical market [13] - The company has received various accolades, including recognition as a unicorn enterprise and a high-tech enterprise, reflecting its strong market position and capabilities [9]

Core Viewpoint - The GLP-1 class drugs, once considered "miracle weight loss drugs," are transitioning from high-priced innovative medications to more accessible healthcare products, with significant price reductions initiated by major pharmaceutical companies like Novo Nordisk and Eli Lilly ahead of patent expirations and increased competition from domestic biosimilars [3][12][14]. Group 1: Price Reduction Dynamics - The recent price reductions for semaglutide and tirzepatide are not isolated incidents but reflect a systematic trend, with semaglutide's lowest price dropping to 329 yuan per injection for the diabetes version and 388 yuan for the weight loss version, marking a significant decrease from previous market prices [4][10]. - Eli Lilly's tirzepatide has also shown price adjustments, with the lowest price for the 2.4ml:10mg version falling below 500 yuan, indicating a clear downward trend in pricing [6][10]. - The price of semaglutide has nearly halved compared to mainstream market prices from a year ago, highlighting the competitive pricing strategies being employed [10]. Group 2: Strategic Market Positioning - The price adjustments by Novo Nordisk and Eli Lilly are viewed as strategic moves to preemptively address the impending competition from biosimilars and domestic innovations, with experts suggesting that these companies are attempting to lock in user bases and enhance patient loyalty [12][13]. - The upcoming expiration of semaglutide's core patent in 2026 is prompting these companies to adjust their pricing strategies to maintain market share against the anticipated influx of biosimilars [13][14]. - The competitive landscape is expected to intensify as more biosimilars enter the market, with predictions of price reductions of 20%-50% for these products [13]. Group 3: Emerging Competitors - Domestic companies like Innovent Biologics and HengRui Medicine are positioned to challenge the original branded products, with Innovent's mazhitide already approved for both weight loss and diabetes indications, and HengRui's dual-target drug HRS9531 expected to receive approval soon [15][17]. - The market is anticipated to see a surge in biosimilars and innovative domestic drugs, with over 10 companies having their applications accepted for semaglutide biosimilars, indicating a crowded competitive environment by 2026 [14][15]. Group 4: Future Market Trends - The domestic weight loss drug market is projected to enter a phase characterized by multiple products coexisting and price stratification, with oral formulations expected to play a crucial role in market expansion [19][20]. - Novo Nordisk's oral semaglutide is set to launch in early 2026, with clinical data showing significant weight loss potential, which may attract a broader patient demographic [19][20]. - The market is still underpenetrated, with only about 1% of the obese population currently using GLP-1 drugs, suggesting substantial growth potential as competition increases [21].

Core Viewpoint - The approval of the clinical trial for the biosimilar Y225 marks a significant advancement for the company in the treatment of Hemophilia A, potentially filling a gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars [1][2] Group 1: Product Development - The clinical trial for Y225, a biosimilar to the drug Shuyou Lile (Emicizumab), has been approved by the National Medical Products Administration (NMPA) of China [1] - Y225 is designed to treat Hemophilia A, a condition caused by a deficiency of coagulation factor VIII, which leads to bleeding disorders [1] - The original drug Shuyou Lile is the only bispecific antibody available for preventive treatment in patients with or without factor VIII inhibitors, but its high cost limits accessibility for patients [1] Group 2: Competitive Advantage - The company has innovatively overcome the formulation patent of the original drug, allowing Y225 to potentially launch seven years earlier than expected, making it the first biosimilar of Shuyou Lile in the domestic market [1] - The existing patents for the original drug extend its protection until 2038, creating a high barrier to entry for competitors [1] Group 3: Strategic Collaborations - A strategic cooperation agreement was signed with Hubei Jiangxia Laboratory to leverage their research capabilities alongside the company's experience in antibody drug development [2] - The collaboration will focus on innovative antibody molecular design, efficient production process development, and clinical research, with Y225 as the first project [2] - This partnership aims to enhance the overall research and development efficiency and long-term industrialization potential of the company's pipeline [2]

Core Viewpoint - The approval of the clinical trial for the biosimilar Y225 marks a significant advancement for the company in the treatment of Hemophilia A, potentially filling a gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars [1][2] Group 1: Product Development - The clinical trial for Y225, a biosimilar to the drug Shuyou Lile® (Emicizumab injection), has been approved by the National Medical Products Administration (NMPA) of China, with the trial set to begin on December 23, 2025 [1] - Y225 is designed to treat Hemophilia A, a condition caused by a deficiency in coagulation factor VIII, which leads to bleeding disorders [1] - The original drug Shuyou Lile® is the only bispecific antibody approved for preventive treatment in patients with or without factor VIII inhibitors, but its high cost limits patient access [1] Group 2: Competitive Advantage - The company has innovatively overcome the formulation patent of the original drug, allowing Y225 to potentially launch seven years earlier than expected, making it the first biosimilar of Shuyou Lile® to enter the domestic market [1] - The existing patents for Shuyou Lile® extend its protection until 2038, creating a significant barrier to entry for competitors [1] Group 3: Strategic Partnerships - A strategic cooperation agreement was signed with Hubei Jiangxia Laboratory on June 17, 2025, to leverage the laboratory's research capabilities alongside the company's experience in antibody drug development [2] - The collaboration will focus on innovative antibody molecule design, efficient production process development, and clinical research, with Y225 as the first project [2] - This partnership aims to enhance the overall research and development efficiency and long-term industrialization potential of the company's pipeline [2]

Core Viewpoint - Youzhiyou Biotech-B (02496.HK) has received approval from the National Medical Products Administration (NMPA) of China for the clinical trial application of its biosimilar Y225, aimed at treating Hemophilia A [1][2] Group 1: Product and Market Potential - Y225 is a biosimilar of the dual-specific antibody Shuyou Lile® (Emicizumab injection), which targets FIX and FX for the treatment of Hemophilia A [1] - The original drug Shuyou Lile® is the only dual antibody medication available for preventive treatment in patients with or without factor VIII inhibitors, offering advantages such as once every four weeks dosing and subcutaneous injection [1] - The high cost of Shuyou Lile® limits patient access, and over 20% of Hemophilia A patients develop inhibitors that affect treatment efficacy [1] - The original drug has a patent protection period extended to 2038, but the company has innovatively overcome the formulation patent, allowing Y225 to potentially launch seven years earlier, filling a gap in the domestic market for high-barrier biosimilars [1] Group 2: Clinical Trial Details - The approved clinical trial is a randomized, double-blind, single-dose, parallel-comparison study assessing the bioequivalence of Shuyou Lile® and Y225 in healthy male subjects [2] - The trial is led by Dr. Huang Chaolin from Wuhan Jinyintan Hospital as the principal investigator [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 WUHAN YZY BIOPHARMA CO., LTD. Y225「艾美賽珠單抗注射液」取得NMPA的IND批准 本 公 告 由 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司（「本 公 司」， 連 同 其 附 屬 公 司 ， 統 稱 「本 集團」）自 願作 出 ，以 告知 本 公司 股東 及 潛在 投 資者 有關 本 公司 的 最新 業務 發 展情況。 本公司欣然宣佈，於2025年12月23日，其生物類似藥Y225的臨床試驗（「IND」）申 請已獲中華人民共和國國家藥品監督管理局（「NMPA」）批准。 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 香港聯合交易所有限公司證券上市規則第18A .05條規定的示警聲明：本公司無法 保證能 ...